Australia's most trusted
source of pharma news
Posted 8 October 2025 AM
The PBAC's November Agenda has been updated, revealing the addition of Taiho's bile duct cancer drug Lytgobi, marking the company's third pitch at winning a recommendation this year.
Already knocked back in both March and July, Taiho is again seeking to have Lytgobi recommended by the PBAC for the treatment of patients with locally advanced or metastatic cholangiocarcinoma (CCA) - commonly known as bile duct cancer - who have previously progressed on systemic therapy and have a fibroblast growth factor receptor 2 fusion or rearrangement.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.